Grifols, S.A. (BME:GRF)

Market Cap	5.07B
Revenue (ttm)	7.21B
Net Income (ttm)	156.92M
Shares Out	680.41M
EPS (ttm)	0.23
PE Ratio	35.35
Forward PE	10.38
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,653,781
Average Volume	1,806,890
Open	8.16
Previous Close	8.16
Day's Range	8.08 - 8.19
52-Week Range	7.32 - 11.35
Beta	0.93
RSI	42.51
Earnings Date	May 5, 2025

About Grifols

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A an...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1909
• Employees: 23,833
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: GRF

Financial Performance

In 2024, Grifols's revenue was 7.21 billion, an increase of 9.41% compared to the previous year's 6.59 billion. Earnings were 156.92 million, an increase of 270.81%.